High Flow Nasal Cannula Market Projected to Reach $1.44 Billion by 2031

According to a report by MarketsandMarkets, the global High Flow Nasal Cannula (HFNC) market is projected to expand from USD 0.94 billion in 2026 to USD 1.44 billion by 2031, representing a compound annual growth rate (CAGR) of 8.9%. North America accounted for the largest share of the market in 2025. Market growth is primarily driven by the rising prevalence of acute and chronic respiratory disorders and increasing demand for non-invasive respiratory support across intensive care and emergency settings.

By application, the acute respiratory failure treatment segment accounts for the largest market share and is projected to lead throughout the forecast period. On the end-user front, hospitals hold the dominant position due to high patient volumes requiring critical care and the availability of specialized medical infrastructure. Furthermore, consumables and accessories accounted for a larger market share than systems in 2025, reflecting a business model centered on capital equipment placement paired with recurring consumable sales.

Key players operating in the HFNC market include Fisher & Paykel Healthcare Limited, Vapotherm, ResMed, Hamilton Medical AG, and Drägerwerk AG & Co. KGaA. The market features a combination of large diversified respiratory-care manufacturers and specialized high-flow technology companies.

Recent corporate transactions highlights investment and commercial activities across the sector. Telesair secured an exclusive US distribution agreement with Tri-anim Health Services in May 2025 for its Bonhawa platform. In September 2024, Vapotherm completed a take-private merger to resolve liquidity constraints and restructure its capital, while Fisher & Paykel Healthcare committed to a NZD 250 million infrastructure investment in March 2025 to expand its R&D, manufacturing, and distribution capabilities.